FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296301712> ?p ?o ?g. }

• W4296301712 endingPage "1250" @default.
• W4296301712 startingPage "1241" @default.
• W4296301712 abstract "Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in ≥10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms.The authors sought to investigate the determinants of DCB failure in femoropopliteal disease.Data from randomized clinical trials (IN.PACT SFA, MDT-2113 SFA Japan) and 2 prespecified imaging cohorts of the IN.PACT Global Clinical Study were included. Influential procedural characteristics were evaluated by an independent angiographic core laboratory. The primary endpoint was DCB failure (patency loss during follow-up). Additional endpoints were binary restenosis and clinically driven target lesion revascularization. Multivariable analyses evaluated the clinical, anatomical, and procedural predictors of DCB failure.Included were 557 participants with single lesions and 12-month core laboratory-adjudicated duplex ultrasonography. Key clinical characteristics were as follows: mean age 68.8 years, 67.5% male, 87.6% with hypertension, 76.9% with hyperlipidemia, 40.5% with diabetes mellitus, 90.5% in Rutherford Classification Category (RCC) 2 to 3, and 9.5% in RCC 4 to 5. Average length and reference vessel diameter (RVD) were 16.37 cm and 4.66 mm, respectively; 49.7% of lesions were totally occluded. In multivariable analysis, only residual stenosis >30% was associated with patency loss, whereas residual stenosis >30% and smaller preprocedure RVD were associated with increased binary restenosis risk. RCC >3 and residual stenosis >30% were associated with increased 12-month clinically driven target lesion revascularization risk.Patency loss after DCB treatment was influenced by procedural and clinical factors. Residual stenosis >30%, smaller preprocedure RVD, and higher RCC may be considered predictors of increased risk of DCB failure and its components in femoropopliteal artery disease. (Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery [MDT-2113 SFA]; NCT01947478; IN.PACT Global Clinical Study; NCT01609296)." @default.
• W4296301712 created "2022-09-19" @default.
• W4296301712 creator A5006083917 @default.
• W4296301712 creator A5015549590 @default.
• W4296301712 creator A5016168216 @default.
• W4296301712 creator A5016620644 @default.
• W4296301712 creator A5019229545 @default.
• W4296301712 creator A5023019539 @default.
• W4296301712 creator A5027062888 @default.
• W4296301712 creator A5034232140 @default.
• W4296301712 creator A5051628311 @default.
• W4296301712 creator A5057962046 @default.
• W4296301712 creator A5059377855 @default.
• W4296301712 creator A5059960901 @default.
• W4296301712 creator A5074927474 @default.
• W4296301712 creator A5076495125 @default.
• W4296301712 creator A5078452184 @default.
• W4296301712 creator A5084293849 @default.
• W4296301712 creator A5086939418 @default.
• W4296301712 date "2022-09-01" @default.
• W4296301712 modified "2023-09-26" @default.
• W4296301712 title "Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention" @default.
• W4296301712 cites W1514973749 @default.
• W4296301712 cites W1944762875 @default.
• W4296301712 cites W1982555723 @default.
• W4296301712 cites W1990142951 @default.
• W4296301712 cites W2071658386 @default.
• W4296301712 cites W2084214097 @default.
• W4296301712 cites W2118501388 @default.
• W4296301712 cites W2156343775 @default.
• W4296301712 cites W2252733902 @default.
• W4296301712 cites W2259741399 @default.
• W4296301712 cites W2583026569 @default.
• W4296301712 cites W2606784939 @default.
• W4296301712 cites W2739447339 @default.
• W4296301712 cites W2771233039 @default.
• W4296301712 cites W2778100912 @default.
• W4296301712 cites W2785472456 @default.
• W4296301712 cites W2791328714 @default.
• W4296301712 cites W2803839738 @default.
• W4296301712 cites W2894238119 @default.
• W4296301712 cites W2905249891 @default.
• W4296301712 cites W2920349555 @default.
• W4296301712 cites W2947332499 @default.
• W4296301712 cites W2954074849 @default.
• W4296301712 cites W3003770534 @default.
• W4296301712 cites W3082920146 @default.
• W4296301712 cites W3114433746 @default.
• W4296301712 cites W3166747195 @default.
• W4296301712 cites W4243204328 @default.
• W4296301712 cites W956910018 @default.
• W4296301712 doi "https://doi.org/10.1016/j.jacc.2022.06.043" @default.
• W4296301712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36137674" @default.
• W4296301712 hasPublicationYear "2022" @default.
• W4296301712 type Work @default.
• W4296301712 citedByCount "6" @default.
• W4296301712 countsByYear W42963017122022 @default.
• W4296301712 countsByYear W42963017122023 @default.
• W4296301712 crossrefType "journal-article" @default.
• W4296301712 hasAuthorship W4296301712A5006083917 @default.
• W4296301712 hasAuthorship W4296301712A5015549590 @default.
• W4296301712 hasAuthorship W4296301712A5016168216 @default.
• W4296301712 hasAuthorship W4296301712A5016620644 @default.
• W4296301712 hasAuthorship W4296301712A5019229545 @default.
• W4296301712 hasAuthorship W4296301712A5023019539 @default.
• W4296301712 hasAuthorship W4296301712A5027062888 @default.
• W4296301712 hasAuthorship W4296301712A5034232140 @default.
• W4296301712 hasAuthorship W4296301712A5051628311 @default.
• W4296301712 hasAuthorship W4296301712A5057962046 @default.
• W4296301712 hasAuthorship W4296301712A5059377855 @default.
• W4296301712 hasAuthorship W4296301712A5059960901 @default.
• W4296301712 hasAuthorship W4296301712A5074927474 @default.
• W4296301712 hasAuthorship W4296301712A5076495125 @default.
• W4296301712 hasAuthorship W4296301712A5078452184 @default.
• W4296301712 hasAuthorship W4296301712A5084293849 @default.
• W4296301712 hasAuthorship W4296301712A5086939418 @default.
• W4296301712 hasBestOaLocation W42963017121 @default.
• W4296301712 hasConcept C126322002 @default.
• W4296301712 hasConcept C126838900 @default.
• W4296301712 hasConcept C139059822 @default.
• W4296301712 hasConcept C141071460 @default.
• W4296301712 hasConcept C164705383 @default.
• W4296301712 hasConcept C168563851 @default.
• W4296301712 hasConcept C203092338 @default.
• W4296301712 hasConcept C2778283817 @default.
• W4296301712 hasConcept C2778583881 @default.
• W4296301712 hasConcept C2779464278 @default.
• W4296301712 hasConcept C2780007028 @default.
• W4296301712 hasConcept C2780326628 @default.
• W4296301712 hasConcept C2780400711 @default.
• W4296301712 hasConcept C2781156865 @default.
• W4296301712 hasConcept C2781464078 @default.
• W4296301712 hasConcept C500558357 @default.
• W4296301712 hasConcept C71924100 @default.
• W4296301712 hasConceptScore W4296301712C126322002 @default.
• W4296301712 hasConceptScore W4296301712C126838900 @default.
• W4296301712 hasConceptScore W4296301712C139059822 @default.
• W4296301712 hasConceptScore W4296301712C141071460 @default.

• next